Recent advances in immunological understanding have re-evaluated the role of suppression and demonstrated that pathogenic T cells can be actively countered by regulatory CD4 + CD25 +
FoxP3
+ T cells (T reg ) in murine models (11) .
In these situations the development of allergic airway inflammation is due to inadequate, defective or overwhelmed T reg responses. These models provide powerful tools to study the influence of the suppressive or trophic function of MSC. If MSC induction of CD4 + CD25 + FoxP3 + cells in vitro (12, 13 ) is mirrored in vivo, then the ovalbumin (OVA) sensitization model offers a means to test the biological significance of MSC as cell therapeutic inhibitors of allergic airway pathology. This study addressed the hypothesis that adult bone marrow derived-MSC would prevent the pathology associated with allergen-driven airway inflammation, and sought to define the effector mechanism. Adult bone marrow derived allogeneic MSC actively prevented the induction of allergendriven pathology in a murine model via induction of T reg suggesting a novel cell therapy for allergic human disease.
Materials and methods

Animals
Allergen sensitization was as previously described (14) using 8-to 12-week old, female BALB/cOlaHsd (H-2 d ) mice (Harlan, Oxon, UK), whereas FVB/NHanHsd (H-2 q ) male mice were the source of allogeneic MSC. Mice were maintained according to the regulations of the Irish Department of Health, and the institutional research ethics committee. Mice were sensitized by intra-peritoneal injection of 100 lg/ ml ovalbumin (OVA) emulsified in aluminum hydroxide (AlumImject TM ) (Pierce, IL, USA) on days 0, 7 and 14. Mice were challenged intra-nasally with OVA (50 lg/ml) or sterile PBS (sham) on days 14, 25, 26 and 27 (Fig. 1A ).
Isolation and culture of bone marrow derived mesenchymal stem cells
Bone marrow from of FV/BN mice was resuspended in Mesencult Basal Medium, supplemented with 10% (v/v) Mesencult supplement (Stem Cell Technologies, Vancouver, Canada). Cells were maintained as previously described (15) , and used between passages 4 and 9 with rigorous purification and quality control to ensure purity as previously described (15) . All MSC used were capable of differentiation to the three major mesenchymal lineages (13) , and were MHC class I + , Sca-1
) and CD117 MSC; (vi) control sham PBS-sensitized with PFA-fixed MSC (Fig. 1A) . MSC locating to the airways within 24 h as previously documented (16) and data not shown. At 28 days, bronchoalveolar lavage fluid, and histopathological studies were performed, serum collected and splenocytes re-stimulated in vitro (14) . All experiments were performed at least twice.
Histopathology and airway physiology
At 28 days BALF was collected (14) and differential cell counts performed as described (14) . Nonlavaged lungs were fixed, sectioned and stained with hematoxylin/eosin (H&E), or combined Discombes/Alcian blue/ periodic acid-Schiff (PAS) stain (14) . Pathology was scored using a semi-quantitative scoring system as mild, moderate or severe and shown for convenience in Supporting information (Fig. S2) . Lung function was assessed by unrestrained plethysmography and expressed as the surrogate index of enhanced pause (PenH) as previously described (14) . This approach has limitations and was used as supporting rather than a definitive indicator of airway hyper-responsiveness.
Measurement of cytokines and antibody response
IL-4, IL-10 and IL-13 from BALF or antigen re-stimulated or control splenocyte supernatants were analyzed by flow cytometry (Becton-Dickinson, New Jersey, USA), using Cytometric Bead Array Flex Sets (BD Biosciences, Franklin Lakes, NJ, USA) according to manufacturer's instructions. Standard curves and raw data were generated for each cytokine using FCAP Array v1.0.1 software (BD Biosciences). OVA-specific serum IgE was measured by ELISA as previously optimized (17) . 
T reg depletion and assessment
In T reg studies, mice were sensitized with OVA on day 0, 7 and 14, and MSC delivered on days 7 and 14. An established model of pharmacological T reg depletion was employed (18 
Statistical analysis
Values for all measurements were expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using graphpad prism TM software (GraphPad, San Diego, CA, USA). Comparison was made using the Kruskal-Wallis test, or the Mann-Whitney test as appropriate. Significance was denoted by P-value <0.05.
Results
Allogeneic MSC therapy reduces allergen-driven airway pathology
The influence of MSC cell therapy was examined in a murine model of allergic pathology. Nonsensitized control mice exhibited no allergen-driven airway inflammation as expected ( Fig. 2A) , whereas OVA-sensitized mice exhibited typical peribronchial and perivascular inflammation (Fig. 2B ). In contrast, MSC therapy resulted in markedly decreased pathology, with decreased peribronchial inflammation ( Fig. 2  C) . Consistent with these data were physiological observations of a surrogate of airway hyper-responsiveness suggesting that MSC therapy reduced bronchial hyper-reactivity compared to OVA-sensitized mice (Fig. S3 ). However MSC needed to be viable as delivery of PFA-fixed MSC to allergen sensitized mice resulted in more severe pathology when compared to OVA-sensitized mice, displaying strong perivascular inflammation and bronchiolar epithelial hypertrophy (Fig. 2D ). Thus MSC cell therapy reduces classical allergendriven pathology in this model. A consistent feature of asthma is the production of mucus blockage of the peripheral airways (19) . MSC delivery reduced airway mucus, whereas PFA-fixed MSC exacerbated goblet cell hyperplasia and mucus secretion in allergen-sensitized mice ( Fig. 2E-H ). Thus live, but not fixed, MSC therapy reduced multiple characteristic aspects of allergen-driven airway pathology.
Allogeneic MSC therapy protects against allergen-driven lung eosinophilia
A cardinal feature of allergen-driven airway inflammation is the elevated number of inflammatory cells in the lungs, particularly eosinophils (9) . Control mice showed minimal cellularity in bronchoalveolar lavage (Fig. 2) , whereas OVA sensitization resulted in significant infiltration (P < 0.05).
Total cellular infiltration was decreased in OVA-sensitized mice that received MSC, whereas it remained high in sensitized animals treated with PFA-fixed MSC. BALF from control mice had few cells, other than macrophages; however OVA sensitization/challenge resulted in eosinophilic inflammation. Airway eosinophilia was significantly reduced in OVA sensitized mice following MSC delivery (P < 0.05), whereas PFA-fixed MSC treatment caused a considerable increase in airway eosinophilia when compared to OVA sensitized mice (Fig. 2) . The number of macrophages in BALF was similar to controls. These findings demonstrated that live allogeneic MSC have wide ranging therapeutic influence on allergen-driven airway inflammation and in particular eosinophilic inflammation.
Allogeneic MSC cell therapy induces T reg in vivo and modulates allergen-specific immunity
IgE induction is a feature of allergen-driven pathologies and OVA sensitization induces IgE and an allergen-specific Th2 response (20) . The capacity for MSC to influence IgE induction was examined by measuring OVA-specific IgE in serum from OVA-sensitized mice in which MSC were used therapeutically. Allogeneic MSC therapy suppressed the allergen-specific IgE response (Fig. 3) , in comparison to mice sen- Figure 3 OVA-specific IgE in serum elicited in response to OVA sensitization. Sera were collected on day 28 and OVA-specific serum IgE levels were measured by ELISA. The data are representative of three experiments; in each case, at least five animals were assessed, and each individual assessment was performed independently in triplicate. Concentrations below 200 pg/ml were considered negative. Results are expressed as mean antibody concentrations ± SEM (**P < 0.01, ***P < 0.001).
sitized to OVA alone (P < 0.05) (Fig. 3) . Sensitized mice that received PFA-fixed MSC showed similar levels of OVA specific IgE to OVA sensitized mice. The phenomena described above might be explained by MSC-mediated global, nonspecific immune suppression or by MSC interference in immune induction. Therefore, the effect of allogeneic MSC on T cell mediated immunity was examined. Particular attention was given to IL-4 and IL-13 induction as these play well defined roles in allergen-driven pathology (21) . As expected, IL-4 and IL-13 in both BALF and splenocyte supernatants were significantly higher in the OVA compared to sham-sensitized mice (Fig. 4) . However, a marked reduction in IL-4 and IL-13, but a significant increase in IL-10 ( Fig. 4) (P < 0.05) was observed in BALF ( Fig. 5B) (P < 0.05) . Similarly, when spleen cells were restimulated ex vivo with allergen, IL-10 was increased but a reduction in IL-13 and IL-4 was observed. This was an important observation as it shows that the protective effect of MSC was a result of targeted, specific modulation of local immunity rather than a global suppression of the immune response.
The induction of local and systemic IL-10 strongly suggested that MSC were inducing a regulatory T cell population. Therefore, the generation and expansion of T reg subsets was assessed in the lungs and spleens of OVA-sensitized mice, and mice that received MSC therapy. MSC induced or expanded a population of regulatory cells; most notably a CD4 Responses are representative of triplicate experiments, each of which were determined independently from at least nine mice per group and are expressed as means ± SEM (*P < 0.05).
and spleen from sensitized, MSC-treated mice (Fig. 5) . A significant increase in FoxP3 expression (P < 0.05) was observed in CD4 + T cells from MSC-treated compared to untreated sensitized mice providing evidence that MSC induce T reg populations in vivo.
Regulatory T cells are required for MSC mediated inhibition of allergic airway inflammation
Detection of T reg does not necessarily equate to an essential function. To investigate whether MSC exerted their immunosuppressive function via induction of T reg , these suppressor cells were depleted and the effect of MSC delivery on airway pathology was examined. Pharmacological depletion based on cyclophosphamide (CY) administration has been widely used to examine the effect of T reg depletion in disease models (22) as it both impairs functionality and depletes T reg in vivo (23) . Fortunately MSC are ALDH + (24) and thus, resistant to CY (25) , and showed no impairment in differentiation capacity to CY during in vitro exposure (data not shown). A protocol consistent with previous studies (18) was chosen to allow OVA-specific effector cell induction but which depleted T reg (Fig. 1B) . Contrary to earlier findings, MSC did not confer protection when T reg were depleted. In the absence of T reg , MSC-treated OVA-sensitized mice displayed significant cellular infiltration including peribronchial inflammation at day 28 ( Fig. 6 ) comparable to allergen sensitized mice. Delivery of MSC in the absence of T reg also resulted in more pronounced levels of mucus production with some airways showing profound obstruction (Fig. 6) . When mice were depleted of T reg , there was no observable difference in IgE between those that received MSC and positive controls (Fig. 6) . These data support a model where atopic responses are moderated in vivo by the suppressive influence of constitutive T reg , and more importantly that T reg were required for the MSC-mediated reduction of pathology and allergen specific IgE. MSC cell therapy in T reg -depleted allergen sensitized mice did not alter the Th2 profile (of IL-4 or -13) in BALF (Fig. 6 ) and did not elevate IL-10, in direct contrast to when T reg were not depleted (Fig. 4) . Similarly, MSC therapy in T reg -depleted mice did not impact on allergen-specific Th2 responses in the spleen. Taken together these data strongly suggest that the mechanism of beneficial action by MSC in this model is dependent on the induction of T reg . Thus MSC modulate allergen specific local and systemic immunity through a T reg mechanism. A feature of CY treatment in this model is enhanced pathology and increased airway eosinophilia (18) . Similar findings are reported here (Fig. 6) . However, MSC treatment significantly reduced eosinophilia even in the absence of T reg (Fig. 6 ), but did not influence other indices or improve overall pathology. Together these data indicate that whilst T reg induction is required to moderate Th2-driven inflammation, an alternative T reg independent mechanism might also be employed by MSC.
Discussion
This study demonstrated that adult bone marrow-derived allogeneic MSC actively prevent the induction of allergendriven pathology through a T reg -dependent mechanism. Systemic administration of MSC protected the airways from OVA-induced pathology evidenced by reduced lung pathology and cellular inflammation in BALF and reduced allergen specific IgE. MSC were not globally immunosuppressive but rather immunomodulatory, inducing splenic OVA recall responses dominated by IL-10, a cytokine also elevated in BALF by MSC therapy. MSC therapy induced populations of CD4 +
FoxP3
+ T cells in the lung and spleen. Depletion of T reg ablated the protective effect of MSC therapy in terms of the major indices of pathology, and restored class switching to IgE. Thus T reg are required for the protective effect of MSC therapy in this model, however MSC continued to affect eosinophilia indicating that MSC also use T reg -independent mechanisms to modulate effector function. The mechanisms of MSC effector action (and hierarchy) in vivo are poorly understood. MSC can induce direct repair, may be cytoprotective, pro-angiogenic, anti-fibrotic or act through other paracrine effects (6, 7, 16) . We have previously outlined mechanisms by which MSC induce T reg in vitro, defining roles for cell contact, TGF-b and PGE-2 (13). This T reg are critical for control of antigen-specific inflammation [for review (27) ] and their recruitment into the airways can suppress allergic airway inflammation (28) . Recently, IL-10 production by T reg was shown to be essential to control immune responses in the lung (29) . The current study revealed that MSC therapy increased CD4 + FoxP3 + T cells in lung and spleen which was associated with elevated IL-10 supporting the findings of Rubstov with regard to the importance of T reg /IL-10, but more importantly strongly suggesting that MSC induction of T reg was not simply an in vitro phenomenon. T reg cell induction in vitro or even in vivo by MSC is an important and interesting finding but its significance depends on the functional contribution to reduced pathology. Here, the contribution of T reg , induced by MSC, to exert functional protection was studied using the cyclophosphamide depletion model. Alternative approaches such as CD25 depletion could not be used as these would interfere with T cell activation and Th2 induction and confound interpretation, whereas this regime differentially depletes functional T reg (30) . Using this model it was shown that T reg induced by allogeneic MSC therapy were required for the reduction in pathologic score, mucus secretion and allergen-induced IgE. Thus, this study goes beyond demonstrating T reg induction in vivo by MSC to show a biological significance for that process. T reg depletion ablated most of the beneficial effects of MSC therapy, indicating the mechanism of protection in this model. However MSC supported a significant reduction in airway eosinophilia despite T reg depletion (Fig. 6 ). This observation was important for two reasons: firstly it indicated that MSC could modulate effector cell function by alternative T reg -independent mechanisms; secondly as reduced eosinophilia is seen here whilst the pathology is impaired, it suggests that altered eosinophilia cannot account for the MSC-mediated effects seen in Fig. 2 , and that the primary mechanism by which MSC reduce pathology is via T reg induction. We and others have previously shown that MSC express a variety of immunosuppressive cytokines including hepatocyte growth factor (HGF) at concentrations that can suppress allogeneic responses in vitro (31) . HGF negatively regulates allergic airway inflammation and hyper-responsiveness (32) via direct attenuation of eosinophil chemotactic function. The expression of HGF by MSC (31, 33) and reduced eosinophilia is consistent with such a T reg -independent role, and consistent with human clinical studies where reduced airway eosinophilia had little impact on pathology (34) . The implication of an alternative MSC mechanism of action is that MSC therapy may allow a targeting of complex multi-factorial diseases that involves both fibrotic and inflammatory processes and T reg -dependent and independent aspects. Allogeneic MSC possess specific immunomodulatory properties that target critical pathogenic features for the development of allergic asthma. Here we demonstrate the efficacy of MSC based cell therapy in a well characterized murine model. We also illustrate the mechanism of action by which protection is mediated as a proof of concept for MSC based immunotherapy for a broad range of diseases where chronic inflammation results in pathology. expression. Mice were given 150 mg/kg of CY intraperitoneally at day 0. Spleen cells were isolated followed by intra/ extracellular labeling of anti-FoxP3-PE/anti-CD4-Cy5 then analyzed by flow cytometry. Results are expressed as mean values ± SD obtained from groups of at least three mice and are representative of two independent experiments. *P < 0.05; **P < 0.005. Figure S4 . Airway responsiveness was assessed on day 37 by methacholine induced airflow obstruction from conscious mice using whole-body plethysmography in conjunction with the BioSystem XA software (Buxco Electronics, USA) as previously described (14) . ( Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
CY-PBS
Acknowledgment
